ImaginAb completes licensing agreement with UCLA

ImaginAb and the University of California, Los Angeles (UCLA) have concluded a technology licensing agreement relating to novel fluorine chemistry for the rapid and robust labeling of proteins, peptides and biomolecules for diagnostic imaging with PET.

The licensed technology originates from the UCLA's Crump Institute for Molecular Imaging through research sponsored by the U.S. Department of Energy. The agreement grants exclusivity to ImaginAb for antibodies and antibody fragments, according to the Inglewood, Calif.-based company.

Around the web

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.